NCT03415802View on ClinicalTrials.gov

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 11, 2015

Primary Completion Date

July 11, 2017

Study Completion Date

July 11, 2019

Conditions
Advanced Pancreatic Cancer
Interventions
DRUG

Nab-paclitaxel and S-1

Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-14, q3w)

Trial Locations (1)

Unknown

National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Aiping Zhou

UNKNOWN

NCT03415802 - Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter